Immune-mediated processes in neurodegeneration: where do we stand?

被引:0
|
作者
Marc Fakhoury
机构
[1] Université de Montréal,Department of Neurosciences, Faculty of Medicine
来源
Journal of Neurology | 2016年 / 263卷
关键词
Immune response; Inflammation; Microglia; Neurodegenerative diseases; T cells;
D O I
暂无
中图分类号
学科分类号
摘要
Neurodegeneration is a pathological condition that predominantly affects neurons. It represents a large spectrum of disorders with heterogeneous symptoms and distinct clinical features. In addition to the devastating effects it can have on the affected individual, it constitutes a heavy burden to the society in terms of health care costs. Although the exact cause of neurodegeneration is not known, there are plenty of evidences supporting the notion that the immune system is strongly associated with various forms of neurodegenerative diseases. Given the numerous functions of immune cells, a change in their expression can either be beneficial or deleterious to the host. A better understanding of the molecular and cellular processes in neurodegeneration is therefore needed. This could facilitate the development of new therapeutic targets and provide effective means to dampen the progression of neurodegenerative disorders. The overarching aim of this paper is to provide an overview of the roles that the innate and adaptive immune systems play in the central nervous system, and to discuss their beneficial or detrimental effects during neurodegeneration. This paper also critically examines the contribution of immune and inflammatory-mediated responses in the development of neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyloid lateral sclerosis by illustrating key findings from animal and human studies.
引用
收藏
页码:1683 / 1701
页数:18
相关论文
共 50 条
  • [31] Delirium: Where do we stand?
    Pae C.-U.
    Marks D.M.
    Han C.
    Patkar A.A.
    Masand P.
    Current Psychiatry Reports, 2008, 10 (3) : 240 - 248
  • [32] Hyperfractionation: Where do we stand?
    BeckBornholdt, HP
    Dubben, HH
    LiertzPetersen, C
    Willers, H
    RADIOTHERAPY AND ONCOLOGY, 1997, 43 (01) : 1 - 21
  • [33] Tuberculosis: Where do we stand?
    Becx-Bleumink, M
    Broekmans, JF
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1998, 3 (06) : 423 - 424
  • [34] WHERE DO WE STAND ON METRIFICATION
    KIRCHER, KF
    DESIGN NEWS, 1969, 24 (02) : 1 - &
  • [35] Reflections on "Where Do We Stand?"
    Weber, Jennifer L.
    CIVIL WAR HISTORY, 2014, 60 (04) : 404 - 406
  • [36] Biomarkers, Where Do We Stand
    Dixit, Vikash
    Sharma, Payal
    Dhage, Atul Dyandeo
    INDIAN JOURNAL OF PSYCHIATRY, 2015, 57 (05) : S165 - S166
  • [37] Pegasparaginase: where do we stand?
    Zeidan, Amer
    Wang, Eunice S.
    Wetzler, Meir
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (01) : 111 - 119
  • [38] Pharmacovigilance: Where do we stand?
    Peethambaran, K.
    Khanwelkar, C. C.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2010, 4 (03) : 2636 - 2637
  • [39] TUBERCULOSIS - WHERE DO WE STAND
    HOLGUIN, AH
    JOURNAL OF THE AMERICAN COLLEGE OF HEALTH ASSOCIATION, 1968, 17 (02): : 175 - 178
  • [40] QCD - WHERE DO WE STAND
    ALTARELLI, G
    MULTIPARTICLE DYNAMICS 1988, 1988, : 253 - 253